A team of Memorial Sloan Kettering Cancer Center (MSK) researchers have made an important finding about why genetically ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...

Johnson & Johnson delivered a "beat and raise" quarter. Results were bolstered by the new acquisition of Intra-Cellular, ...

Johnson & Johnson has completed its $14.6 billion acquisition of Bedminster-based neurological drugmaker Intra-Cellular Therapies.

Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.

View the latest Intra-Cellular Therapies Inc. (ITCI) stock price, news, historical charts, analyst ratings and financial information from WSJ.

In the preceding three months, 6 analysts have released ratings for Intra-Cellular Therapies (NASDAQ:ITCI), presenting a wide array of perspectives from bullish to bearish.The table below provides ...

Intra-Cellular Therapies ITCI signed a definitive agreement with pharma bigwig Johnson & Johnson JNJ. Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share ...